首页/数据集/Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

ChEBI2016-01-08 更新2026-07-12 收录

HER2阳性乳腺癌耐药性

肿瘤靶向治疗

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-67019 数据链接链接失效反馈

官方服务：

资源简介：

Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer

应用场景：

创建时间：

2016-01-08

肿瘤靶向治疗

药物耐药机制

Protein arginine methyltransferase 5 (PRMT5) over-expression in hematological and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell c

NIAID Data Ecosystem90

Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [HG-U133_Plus_2]

肿瘤靶向治疗

基因表达谱分析

U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ), when tumour is established in BALB/c SCID mice. At the e

NIAID Data Ecosystem50

Autonomous rhythmic activity in glioma networks drives brain tumor growth

胶质母细胞瘤机制

肿瘤靶向治疗

Glioblastoma cell networks harbor a plastic population of highly active glioblastoma cells that display rhythmic Ca2+ oscillations and are particularly connected to others. Targeting the autonomous rh

NIAID Data Ecosystem40

肿瘤靶分子临床研究信息数据集

肿瘤靶向治疗

临床研究

聚焦肿瘤靶分子临床研究全流程，整合靶点发现、临床试验设计、疗效数据、安全性评估等核心信息。数据经标准化清洗与专业校验，关联靶点分子结构、作用机制及临床结果，支持科研机构靶点验证、药企药物研发、临床机构方案优化，为靶分子临床转化提供高质量、可溯源的数据支撑。

江苏数据交易所80

Additional file 8 of RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

HER2阳性乳腺癌耐药性

RANK信号通路

Additional file 8: Supplementary Table 1.

Figshare2021-03-31 更新50